[Federal Register Volume 76, Number 37 (Thursday, February 24, 2011)]
[Notices]
[Page 10381]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-4184]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2) notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The purpose of this meeting is to evaluate requests
for preclinical development resources for potential new therapeutics
for the treatment of cancer. The outcome of the evaluation will provide
information to internal NCI committees that will decide whether NCI
should support requests and make available contract resources for
development of the potential therapeutic to improve the treatment of
various forms of cancer. The research proposals and the discussions
could disclose confidential trade secrets or commercial property such
as patentable material and personal information concerning individuals
associated with the proposed research projects, the disclosure of which
would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel; NCI Experimental Therapeutics Program (NExT) Cycle 7.
Date: April 13, 2011.
Time: 8:30 a.m.-4:30 p.m.
Agenda: To evaluate the NCI Experimental Therapeutics Program
Portfolio.
Place: Marriott North Conference Center, 5701 Marinelli Road,
Rockville, MD 20852.
Contact Person: Dr. Barbara Mroczkowski, Executive Secretary,
NCI Experimental Therapeutics Program, National Cancer Institute,
NIH, 31 Center Drive, Room 3A44, Bethesda, MD 20892, (301) 496-4291,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: February 17, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2011-4184 Filed 2-23-11; 8:45 am]
BILLING CODE 4140-01-P